UTHR SEC Filing News — United Therapeutics Corporation

Latest SEC filings for United Therapeutics Corporation (UTHR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated wit…
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $23.3B
20
Total Filings
0
Bullish Classifications
17
Bearish Classifications
16
Insider Transactions
1
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for UTHR currently lean bearish. Of the 20 filing records displayed, 17 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
UTHR Filing Activity Snapshot 2026-09-30 — 2026-10-16
Insider Transactions (Form 4)
0 buys vs 16 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$113.26M
MARTINE ROTHBLATT · 2026-10-01
209,000 shares · Form 144
Form 144 Notices
3
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 16 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 16 filings in this group are Form 4s for United Therapeutics Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 16 insider filings shown, the breakdown is 16 open-market sale. 16 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×16
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-10-16

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.19M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 281 $540.48 $151.9K
S Open-market sale 1,163 $541.59 $629.9K
S Open-market sale 456 $542.68 $247.5K
S Open-market sale 371 $543.39 $201.6K
S Open-market sale 269 $544.75 $146.5K
S Open-market sale 825 $545.87 $450.3K
S Open-market sale 601 $546.94 $328.7K
S Open-market sale 2,166 $547.83 $1.19M
S Open-market sale 2,039 $548.89 $1.12M
S Open-market sale 1,009 $549.76 $554.7K
S Open-market sale 200 $550.72 $110.1K
S Open-market sale 120 $551.50 $66.2K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.19M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-16

UTHR insider MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares (~$4.52M)

MAHON PAUL A, listed as EVP & GENERAL COUNSEL at UNITED THERAPEUTICS Corp, reported an open-market sale of 8,300 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 8,300 $146.03 $1.21M
S Open-market sale 268 $541.64 $145.2K
S Open-market sale 1,924 $542.49 $1.04M
S Open-market sale 1,983 $543.56 $1.08M
S Open-market sale 791 $544.85 $431.0K
S Open-market sale 2,615 $545.69 $1.43M
S Open-market sale 719 $546.56 $393.0K
M Option exercise derivative · Stock Option 8,300 — —
Filing: Form 4 (Insider Transaction) Insider: MAHON PAUL A (EVP & GENERAL COUNSEL) Shares: 8,300 Est. Value: $4.52M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-15

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.13M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 40 $526.07 $21.0K
S Open-market sale 160 $530.09 $84.8K
S Open-market sale 120 $531.19 $63.7K
S Open-market sale 40 $532.48 $21.3K
S Open-market sale 240 $534.63 $128.3K
S Open-market sale 400 $535.89 $214.4K
S Open-market sale 633 $537.19 $340.0K
S Open-market sale 1,127 $538.00 $606.3K
S Open-market sale 525 $539.09 $283.0K
S Open-market sale 2,002 $540.23 $1.08M
S Open-market sale 1,930 $541.20 $1.04M
S Open-market sale 883 $542.07 $478.6K
S Open-market sale 400 $543.15 $217.3K
S Open-market sale 480 $544.35 $261.3K
S Open-market sale 480 $545.48 $261.8K
S Open-market sale 40 $546.00 $21.8K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.13M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-14

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.18M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 639 $542.76 $346.8K
S Open-market sale 2,340 $543.48 $1.27M
S Open-market sale 1,492 $544.56 $812.5K
S Open-market sale 1,507 $545.52 $822.1K
S Open-market sale 1,452 $546.46 $793.5K
S Open-market sale 630 $547.47 $344.9K
S Open-market sale 698 $548.49 $382.8K
S Open-market sale 502 $549.47 $275.8K
S Open-market sale 160 $550.59 $88.1K
S Open-market sale 80 $551.49 $44.1K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.18M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-13

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.23M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 428 $548.13 $234.6K
S Open-market sale 1,329 $549.01 $729.6K
S Open-market sale 2,565 $550.03 $1.41M
S Open-market sale 2,628 $551.10 $1.45M
S Open-market sale 1,857 $551.92 $1.02M
S Open-market sale 558 $552.93 $308.5K
S Open-market sale 135 $554.46 $74.9K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.23M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-13

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.18M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 120 $531.92 $63.8K
S Open-market sale 320 $533.80 $170.8K
S Open-market sale 640 $534.80 $342.3K
S Open-market sale 400 $536.09 $214.4K
S Open-market sale 360 $537.05 $193.3K
S Open-market sale 400 $538.33 $215.3K
S Open-market sale 200 $539.23 $107.8K
S Open-market sale 320 $540.74 $173.0K
S Open-market sale 40 $541.51 $21.7K
S Open-market sale 240 $543.21 $130.4K
S Open-market sale 400 $544.54 $217.8K
S Open-market sale 400 $545.90 $218.4K
S Open-market sale 240 $546.60 $131.2K
S Open-market sale 878 $548.01 $481.2K
S Open-market sale 2,641 $548.93 $1.45M
S Open-market sale 1,478 $549.93 $812.8K
S Open-market sale 423 $550.72 $233.0K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.18M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-09

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.08M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 200 $525.50 $105.1K
S Open-market sale 767 $526.66 $404.0K
S Open-market sale 273 $527.57 $144.0K
S Open-market sale 200 $528.63 $105.7K
S Open-market sale 199 $530.13 $105.5K
S Open-market sale 1,061 $531.07 $563.5K
S Open-market sale 600 $532.07 $319.2K
S Open-market sale 800 $533.36 $426.7K
S Open-market sale 920 $534.28 $491.5K
S Open-market sale 480 $535.46 $257.0K
S Open-market sale 824 $536.61 $442.2K
S Open-market sale 1,016 $537.53 $546.1K
S Open-market sale 605 $538.60 $325.9K
S Open-market sale 1,091 $539.58 $588.7K
S Open-market sale 424 $540.51 $229.2K
S Open-market sale 40 $541.23 $21.6K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.08M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-08

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.22M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 176 $542.73 $95.5K
S Open-market sale 744 $543.76 $404.6K
S Open-market sale 2,098 $544.82 $1.14M
S Open-market sale 493 $545.85 $269.1K
S Open-market sale 629 $546.94 $344.0K
S Open-market sale 387 $548.18 $212.1K
S Open-market sale 1,173 $549.13 $644.1K
S Open-market sale 874 $550.14 $480.8K
S Open-market sale 486 $551.09 $267.8K
S Open-market sale 440 $552.29 $243.0K
S Open-market sale 185 $553.70 $102.4K
S Open-market sale 485 $554.51 $268.9K
S Open-market sale 930 $555.77 $516.9K
S Open-market sale 400 $556.48 $222.6K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.22M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-07

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.12M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 280 $527.90 $147.8K
S Open-market sale 360 $528.72 $190.3K
S Open-market sale 240 $530.13 $127.2K
S Open-market sale 320 $531.94 $170.2K
S Open-market sale 215 $533.14 $114.6K
S Open-market sale 167 $534.30 $89.2K
S Open-market sale 734 $535.71 $393.2K
S Open-market sale 323 $536.25 $173.2K
S Open-market sale 133 $537.58 $71.5K
S Open-market sale 1,088 $538.61 $586.0K
S Open-market sale 1,606 $539.68 $866.7K
S Open-market sale 2,054 $540.68 $1.11M
S Open-market sale 380 $541.55 $205.8K
S Open-market sale 120 $542.49 $65.1K
S Open-market sale 558 $543.99 $303.5K
S Open-market sale 842 $544.75 $458.7K
S Open-market sale 80 $545.50 $43.6K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.12M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-06

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.15M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 501 $536.26 $268.7K
S Open-market sale 905 $537.43 $486.4K
S Open-market sale 655 $538.62 $352.8K
S Open-market sale 931 $539.50 $502.3K
S Open-market sale 1,028 $540.50 $555.6K
S Open-market sale 1,239 $541.66 $671.1K
S Open-market sale 918 $542.56 $498.1K
S Open-market sale 783 $543.54 $425.6K
S Open-market sale 1,260 $544.59 $686.2K
S Open-market sale 920 $545.69 $502.0K
S Open-market sale 360 $546.63 $196.8K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.15M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-05

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.22M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 700 $542.06 $379.4K
S Open-market sale 408 $542.87 $221.5K
S Open-market sale 1,032 $544.17 $561.6K
S Open-market sale 1,280 $544.90 $697.5K
S Open-market sale 309 $546.75 $168.9K
S Open-market sale 1,171 $547.99 $641.7K
S Open-market sale 1,206 $548.87 $661.9K
S Open-market sale 757 $549.59 $416.0K
S Open-market sale 432 $550.99 $238.0K
S Open-market sale 725 $551.82 $400.1K
S Open-market sale 160 $552.86 $88.5K
S Open-market sale 80 $554.30 $44.3K
S Open-market sale 80 $555.60 $44.4K
S Open-market sale 240 $557.43 $133.8K
S Open-market sale 120 $558.60 $67.0K
S Open-market sale 120 $560.66 $67.3K
S Open-market sale 40 $562.35 $22.5K
S Open-market sale 80 $563.88 $45.1K
S Open-market sale 80 $566.58 $45.3K
S Open-market sale 240 $569.90 $136.8K
S Open-market sale 120 $570.70 $68.5K
S Open-market sale 80 $572.44 $45.8K
S Open-market sale 40 $574.23 $23.0K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.22M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-02

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$5.48M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 120 $560.05 $67.2K
S Open-market sale 80 $561.68 $44.9K
S Open-market sale 160 $563.31 $90.1K
S Open-market sale 94 $567.90 $53.4K
S Open-market sale 306 $569.65 $174.3K
S Open-market sale 534 $570.55 $304.7K
S Open-market sale 320 $571.52 $182.9K
S Open-market sale 560 $572.86 $320.8K
S Open-market sale 280 $573.62 $160.6K
S Open-market sale 830 $574.94 $477.2K
S Open-market sale 1,346 $575.90 $775.2K
S Open-market sale 774 $576.91 $446.5K
S Open-market sale 930 $577.93 $537.5K
S Open-market sale 320 $579.02 $185.3K
S Open-market sale 864 $580.20 $501.3K
S Open-market sale 702 $581.21 $408.0K
S Open-market sale 520 $582.24 $302.8K
S Open-market sale 400 $583.28 $233.3K
S Open-market sale 360 $584.66 $210.5K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $5.48M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-01

UTHR insider MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares (~$4.69M)

MAHON PAUL A, listed as EVP & GENERAL COUNSEL at UNITED THERAPEUTICS Corp, reported an open-market sale of 8,300 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 8,300 $146.03 $1.21M
S Open-market sale 880 $558.30 $491.3K
S Open-market sale 1,480 $560.19 $829.1K
S Open-market sale 780 $561.87 $438.3K
S Open-market sale 1,480 $563.09 $833.4K
S Open-market sale 400 $566.41 $226.6K
S Open-market sale 720 $567.76 $408.8K
S Open-market sale 739 $569.15 $420.6K
S Open-market sale 838 $570.90 $478.4K
S Open-market sale 823 $572.25 $471.0K
S Open-market sale 160 $573.15 $91.7K
M Option exercise derivative · Stock Option 8,300 — —
Filing: Form 4 (Insider Transaction) Insider: MAHON PAUL A (EVP & GENERAL COUNSEL) Shares: 8,300 Est. Value: $4.69M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-01

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 1,920 shares (~$1.06M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 1,920 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 400 $547.29 $218.9K
S Open-market sale 280 $548.25 $153.5K
S Open-market sale 240 $549.40 $131.9K
S Open-market sale 400 $550.47 $220.2K
S Open-market sale 160 $551.50 $88.2K
S Open-market sale 120 $552.63 $66.3K
S Open-market sale 113 $553.78 $62.6K
S Open-market sale 207 $554.70 $114.8K
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 1,920 Est. Value: $1.06M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-01

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 7,580 shares (~$3.93M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 7,580 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 161 $476.14 $76.7K
S Open-market sale 749 $477.43 $357.6K
S Open-market sale 650 $478.47 $311.0K
S Open-market sale 359 $479.67 $172.2K
S Open-market sale 601 $480.79 $289.0K
S Open-market sale 160 $482.36 $77.2K
S Open-market sale 80 $487.79 $39.0K
S Open-market sale 40 $495.32 $19.8K
S Open-market sale 40 $511.37 $20.5K
S Open-market sale 80 $514.90 $41.2K
S Open-market sale 80 $517.16 $41.4K
S Open-market sale 80 $523.36 $41.9K
S Open-market sale 80 $524.62 $42.0K
S Open-market sale 80 $526.09 $42.1K
S Open-market sale 160 $531.11 $85.0K
S Open-market sale 160 $536.52 $85.8K
S Open-market sale 200 $537.67 $107.5K
S Open-market sale 40 $538.65 $21.5K
S Open-market sale 480 $540.78 $259.6K
S Open-market sale 580 $541.76 $314.2K
S Open-market sale 600 $543.25 $325.9K
S Open-market sale 840 $544.05 $457.0K
S Open-market sale 920 $545.13 $501.5K
S Open-market sale 360 $546.23 $196.6K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 7,580 Est. Value: $3.93M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-30

UTHR insider ROTHBLATT MARTINE A (Director, Chairperson & CEO) sold 9,500 shares (~$4.54M)

ROTHBLATT MARTINE A, listed as Director, Chairperson & CEO at UNITED THERAPEUTICS Corp, reported an open-market sale of 9,500 UTHR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,500 $117.76 $1.12M
S Open-market sale 400 $472.05 $188.8K
S Open-market sale 449 $472.97 $212.4K
S Open-market sale 80 $473.86 $37.9K
S Open-market sale 552 $475.12 $262.3K
S Open-market sale 1,395 $476.10 $664.2K
S Open-market sale 2,135 $477.09 $1.02M
S Open-market sale 2,309 $478.10 $1.10M
S Open-market sale 1,200 $479.07 $574.9K
S Open-market sale 160 $479.59 $76.7K
S Open-market sale 500 $481.22 $240.6K
S Open-market sale 120 $482.28 $57.9K
S Open-market sale 200 $486.77 $97.4K
M Option exercise derivative · Stock Option 9,500 — —
Filing: Form 4 (Insider Transaction) Insider: ROTHBLATT MARTINE A (Director, Chairperson & CEO) Shares: 9,500 Est. Value: $4.54M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. United Therapeutics Corporation has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-15

UTHR Form 144 filed for proposed insider sale by PAUL MAHON (8,300 shares) ~$4.52M

PAUL MAHON filed a Form 144 with the SEC indicating intent to sell UTHR (UNITED THERAPEUTICS Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PAUL MAHON Shares: 8,300 Est. Value: $4.52M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-10-01

UTHR Form 144 filed for proposed insider sale by MARTINE ROTHBLATT (209,000 shares) ~$113.26M

MARTINE ROTHBLATT filed a Form 144 with the SEC indicating intent to sell UTHR (UNITED THERAPEUTICS Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: MARTINE ROTHBLATT Shares: 209,000 Est. Value: $113.26M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-10-01

UTHR Form 144 filed for proposed insider sale by PAUL MAHON (8,300 shares) ~$4.69M

PAUL MAHON filed a Form 144 with the SEC indicating intent to sell UTHR (UNITED THERAPEUTICS Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PAUL MAHON Shares: 8,300 Est. Value: $4.69M
View on SEC EDGAR → Open Filing Document →
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for United Therapeutics Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14

UTHR filed 8-K — material company event

UNITED THERAPEUTICS Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →

How we classify United Therapeutics Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on UTHR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — UTHR SEC Filings

More Tools for UTHR

UTHR Full Stock Analysis UTHR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper UTHR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the UTHR stock analysis page.

UTHR Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer